⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL313389 | 1.00 | — | — | |
| SCHEMBL14591141 | 0.80 | — | — | |
| SCHEMBL16511466 | 0.71 | CA1 (0.41) | — | |
| SCHEMBL31596809 | 0.71 | CA1 (0.32) | — | |
| SCHEMBL31596620 | 0.70 | OXTR (0.31) | — | |
| SCHEMBL19191886 | 0.67 | — | — | |
| SCHEMBL13806817 | 0.66 | — | — | |
| SCHEMBL2504146 | 0.66 | CA1 (0.31) | — | |
| SCHEMBL12445110 | 0.65 | — | — | |
| SCHEMBL4810426 | 0.65 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3698797-A1 | MEVALONIC ACID PATHWAY INHIBITOR AND PHARMACEUTICAL COMPOSITION THEREOF | Tsinghua University (CN) | 2020-08-26 | — | — | EP | disclosed |
| WO-2019076269-A1 | MEVALONIC ACID PATHWAY INHIBITOR AND PHARMACEUTICAL COMPOSITION THEREOF | 清华大学 | 2019-04-25 | — | — | WO | disclosed |
| EP-3348269-A1 | MEVALONATE PATHWAY INHIBITOR AS HIGHLY-EFFECTIVE VACCINE ADJUVANT | Tsinghua University (CN) | 2018-07-18 | — | — | EP | disclosed |
| EP-2758401-B1 | AMINO-SUBSTITUTED IMIDAZOPYRIDAZINES | BAYER IP GMBH (DE) | 2017-05-31 | — | — | EP | disclosed |
| EP-3064498-A1 | PYRAZOLOPYRIMIDONE OR PYRROLOTRIAZONE DERIVATIVES, METHOD OF PREPARING SAME, AND PHARMACEUTICAL APPLICATIONS THEREOF | Shanghai Hengrui Pharmaceutical Co. Ltd. (CN) | 2016-09-07 | — | — | EP | disclosed |
| EP-2471773-B1 | Piperidinyl derivatives as modulators of chemokine receptor activity | BRISTOL MYERS SQUIBB CO (US) | 2016-03-23 | — | — | EP | disclosed |
| EP-2995615-A1 | CYCLOPROPYL-FUSED PYRROLIDINE-BASED INHIBITORS OF DIPEPTIDYL PEPTIDASE IV AND THEIR PHARMACEUTICAL USE | AstraZeneca AB (SE) | 2016-03-16 | — | — | EP | disclosed |
| EP-2173713-B1 | Piperidinyl derivatives as modulators of chemokine receptor activity | BRISTOL MYERS SQUIBB CO (US) | 2016-02-17 | — | — | EP | disclosed |
| EP-2272825-B1 | Protected amino hydroxy adamantane carboxylic acid and process for its preparation | ASTRAZENECA AB (SE) | 2015-11-04 | — | — | EP | disclosed |
| EP-2142551-B1 | FUSED HETEROCYCLIC 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE I INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2015-10-14 | — | — | EP | disclosed |
| EP-1989190-B1 | TRIAZINE 11-BETA HYDROXYSTEROID DEHYDROGENASE TYPE I INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2011-04-27 | — | — | EP | disclosed |
| EP-2272825-A2 | N-Protected amino hydroxy adamantane carboxylic acid and process for its preparation | Bristol-Myers Squibb Company (US) | 2011-01-12 | — | — | EP | disclosed |
| EP-1658066-B9 | ADAMANTYLGLYCINE- BASED INHIBITORS OF DIPEPTIDYL PEPTIDASE IV FOR THE TREATMENT OF DIABETES | BRISTOL MYERS SQUIBB CO (US) | 2010-02-24 | — | — | EP | disclosed |
| WO-2010009183-A1 | PYRIDONE AND PYRIDAZONE ANALOGUES AS GPR119 MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-01-21 | — | — | WO | disclosed |
| EP-1658066-B1 | ADAMANTYLGLYCINE- BASED INHIBITORS OF DIPEPTIDYL PEPTIDASE IV FOR THE TREATMENT OF DIABETES | BRISTOL MYERS SQUIBB CO (US) | 2009-09-30 | — | — | EP | disclosed |
| US-7579360-B2 | Compounds are substituted 8-phenoxy-3-(bicyclo)alkyl-1,2,4-triazolo(4,3-a)pyridines; diabetes, hyperglycemia, obesity, dyslipidemia, hypertension, cognitive impairment, rheumatoid arthritis, glaucoma | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-08-25 | — | — | US | disclosed |
| US-7579360-B2 | Compounds are substituted 8-phenoxy-3-(bicyclo)alkyl-1,2,4-triazolo(4,3-a)pyridines; diabetes, hyperglycemia, obesity, dyslipidemia, hypertension, cognitive impairment, rheumatoid arthritis, glaucoma | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-08-25 | — | — | US | disclosed |
| EP-1261586-B1 | CYCLOPROPYL-FUSED PYRROLIDINE-BASED INHIBITORS OF DIPEPTIDYL PEPTIDASE IV, PROCESSES FOR THEIR PREPARATION, AND THEIR USE | BRISTOL MYERS SQUIBB CO (US) | 2008-05-21 | — | — | EP | disclosed |
| EP-1181014-B1 | HETEROCYCLIC CONTAINING BIPHENYL aP2 INHIBITORS AND METHOD | BRISTOL MYERS SQUIBB CO (US) | 2007-05-23 | — | — | EP | disclosed |
| EP-0251714-A2 | Enantioselective synthesis of 1,3,4,6,7,12B(S)-hexahydro-2H-benzo(B) furo (2,3-A) quinolizin-2-one | MERCK & CO. INC. (US) | 1988-01-07 | — | — | EP | disclosed |